We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

88 hedge funds and large institutions have $725M invested in Neumora Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 9

47% more funds holding

Funds holding: 60 → 88 (+28)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

4.5% more ownership

Funds ownership: 28.67% → 33.17% (+4.5%)

3% less capital invested

Capital invested by funds: $745M → $725M (-$20M)

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

83% less call options, than puts

Call options by funds: $75K | Put options by funds: $453K

Holders
88
Holders Change
+28
Holders Change %
+46.67%
% of All Funds
1.27%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
37
Increased
17
Reduced
18
Closed
9
Calls
$75K
Puts
$453K
Net Calls
-$378K
Net Calls Change
-$514K

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$57.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.9M
3
DTC
Deep Track Capital
Connecticut
+$16.2M
4
SCM
Soros Capital Management
New York
+$14.6M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.2M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$29M
2
Goldman Sachs
Goldman Sachs
New York
-$6.95M
3
AI
Alphabet Inc
California
-$6.9M
4
APM
Avidity Partners Management
Texas
-$3.08M
5
GC
GMT Capital
Georgia
-$2.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
SoftBank Group
1
SoftBank Group
Japan
$105M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$103M +$17.9M +1,109,236 +17%
MCMU
3
MIC Capital Management (UK)
United Kingdom
$61.3M – – –
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$49.3M +$57.9M +3,584,004 New
IC
5
Iconiq Capital
California
$46.7M – – –
WT
6
Wellcome Trust
United Kingdom
$45.5M – – –
AG
7
Artal Group
Luxembourg
$40.2M +$6M +371,350 +15%
EC
8
EcoR1 Capital
California
$28.5M – – –
JJ
9
Johnson & Johnson
New Jersey
$25.4M – – –
Citadel Advisors
10
Citadel Advisors
Florida
$25.1M -$312K -19,308 -1%
APM
11
Avidity Partners Management
Texas
$24.8M -$3.08M -190,632 -10%
O
12
OrbiMed
New York
$20.6M – – –
DTC
13
Deep Track Capital
Connecticut
$13.8M +$16.2M +1,000,000 New
BlackRock
14
BlackRock
New York
$13.6M -$945K -58,433 -6%
SCM
15
Soros Capital Management
New York
$12.4M +$14.6M +904,016 New
T. Rowe Price Associates
16
T. Rowe Price Associates
Maryland
$10.4M +$12.2M +752,924 New
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$9.46M +$11.1M +688,169 New
RSCM
18
Rock Springs Capital Management
Maryland
$8.88M +$10.4M +646,118 New
BBA
19
Baker Bros. Advisors
New York
$8.72M +$10.2M +633,851 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$6.22M +$251K +15,504 +4%
LGM
21
Logos Global Management
California
$6.19M – – –
Vanguard Group
22
Vanguard Group
Pennsylvania
$4.6M -$754K -46,624 -12%
AH
23
Addis & Hill
Pennsylvania
$4.19M +$5.09M +314,821 New
State Street
24
State Street
Massachusetts
$3.56M +$1.9M +117,706 +83%
PC
25
Pier Capital
Connecticut
$3.43M +$4.03M +249,336 New
1
2 3 4

NMRA Hedge Fund Activity: Q1 2024 in Review

88 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2024, worth a combined $725M — down 2.7% from $745M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new NMRA positions and 9 closed out — a net gain of 28 holders — while 17 added to existing stakes and 18 trimmed.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $57.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $29M sold.

  • 88 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2024, up from 60 in Q4 2023.
  • Funds reported $725M of Neumora Therapeutics stock for Q1 2024, down 2.7% quarter-over-quarter.
  • 37 funds opened new Neumora Therapeutics positions in Q1 2024 and 9 closed out, a net change of +28 holders.
  • The largest Neumora Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $57.9M added.
  • The largest Neumora Therapeutics seller in Q1 2024 was HHLR Advisors, an estimated $29M sold.

Based on aggregated 13F filings for Q1 2024.